The American journal of managed care
-
To examine US commercial health plans' adoption of 2018 FDA-approved drugs. ⋯ Health plans imposed fewer coverage restrictions on cancer treatments, orphan drugs, and biosimilars than on drugs not in those categories. Some plans covered 2018 FDA-approved drugs more generously than others, which has implications for patients' access to innovative therapies.